Friday, April 10, 2020
In the global race to develop an effective vaccine to protect people against the novel coronavirus, China’s CanSino Bio has leapt ahead. The biotech has started enrollment activities of a phase 2 trial testing its recombinant shot, Ad5-nCoV, in healthy volunteers in the city of Wuhan.
Friday, April 10, 2020
The FDA has granted an emergency authorization to a blood purification system to treat patients with the most severe cases of COVID-19.
Friday, April 10, 2020
Amazon has begun outfitting an in-house COVID-19 testing lab to help screen its frontline warehouse and delivery workers. The retailing giant has already instituted daily temperature checks as more than 100,000 people arrive for work each day.
Friday, April 10, 2020
Amneal, one of many drugmakers pledging millions of tablets of COVID-19 therapy hopeful hydroxychloroquine, is facing an ingredients shortage after the Finnish government locked down exports of the drug.
Friday, April 10, 2020
FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry.
Friday, April 10, 2020
Vir Biotechnology is betting big on its two novel antibodies' potential to treat COVID-19, locking down a range of manufacturing partners to help scale up. Now, in a third major deal, Vir and Samsung will work together to boost production if the treatment proves effective.
Friday, April 10, 2020
Health and Human Services partnered with UnitedHealth Group to deliver $30 billion to providers starting on Friday, hoping for a quick dispersal of the funds providers say are desperately needed to help them combat COVID-19.
Thursday, April 9, 2020
Blue Cross Blue Shield of Michigan is encouraging its medical professionals to volunteer to care for COVID-19 patients—and will pay them to do so.
Friday, April 10, 2020
BioCryst Pharmaceuticals has begun enrolling COVID-19 patients in a clinical trial of its antiviral drug galidesivir. The trial builds on in vitro evidence that the adenosine nucleoside analog is effective against pathogens including the MERS and SARS coronaviruses.
Thursday, April 9, 2020
CMS relaxed a series of rules in the hopes of boosting workforce capacity at provider facilities overwhelmed with the COVID-19 outbreak.
Friday, April 10, 2020
The FDA green-lighted a clinical trial for CalciMedica’s CRAC channel inhibitor in patients with severe pneumonia caused by COVID-19. The drug, CM4620-IE, is designed to settle down an overactive immune system to reduce inflammation, CalciMedica Chief Medical Officer Sudarshan Hebbar, M.D., told FierceBiotech.
